Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Posted by Brian Himes on Jun 4th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00.
On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00.
On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.
On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00.
On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00.

Halozyme Therapeutics Stock Performance

HALO stock opened at $69.82 on Thursday. The company has a market capitalization of $8.28 billion, a P/E ratio of 25.12, a PEG ratio of 0.27 and a beta of 0.88. The company has a 50-day simple moving average of $66.44 and a 200 day simple moving average of $68.71. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current fiscal year.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

Positive Sentiment: Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, suggesting improving profit expectations for Halozyme Therapeutics. Halozyme Therapeutics article
Positive Sentiment: Analysts now see stronger earnings in several quarters, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which may reinforce the stock’s valuation outlook. Halozyme Therapeutics article
Neutral Sentiment: There was also a small increase in one near-term estimate for Q4 2026, while Q2 2026 was trimmed slightly and Q1 2028 was revised lower, indicating a mostly constructive but not uniformly higher forecast profile. Halozyme Therapeutics article
Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were executed under pre-arranged 10b5-1 plans, which usually makes them less concerning to investors than discretionary selling. Halozyme Therapeutics article

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC raised its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Clearstead Advisors LLC raised its position in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares in the last quarter. Harbour Investments Inc. raised its position in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new stake in Halozyme Therapeutics in the third quarter worth about $52,000. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HALO shares. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

View Our Latest Research Report on Halozyme Therapeutics

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.